CliffBio
small molecule

VAPRISOL

CONIVAPTAN HYDROCHLORIDE

Loss of exclusivity—loss of exclusivity
CompanyCumberland →See this company's full patent-cliff portfolio

Drug detail

Brand nameVAPRISOL
Active ingredientCONIVAPTAN HYDROCHLORIDE
Strength20MG/4ML (5MG/ML)
Dosage formINJECTABLE
RouteINTRAVENOUS
ModalitySmall molecule
FDA approvalDecember 2005
Marketing statusDISCN

More from Cumberland

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

VAPRISOL patent cliff — loss of exclusivity — | CliffBio